An update on the EPCORE NHL-1 trial

(1:35)

Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCL

(3:1econd)

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

(1:49)

EPCORE NHL-1: health-related QoL in patients with R/R LBCL treated with subcutaneous epcoritamab

(1:18)

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

(2:30)

Strategies for mitigating CRS risk in DLBCL: preliminary findings from EPCORE NHL-1

(3:21)

EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL

(7:45)

EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL

(1:46)

myTRIAList Clinical Trial: EPCORE NHL-6

(5:9)

Epcoritamab in R/R FL: pooled efficacy data from EPCORE NHL-1

(1:28)

Findings from arms 6 and 7 of the EPCORE NHL-2 trial: epcoritamab in newly diagnosed FL

(8:6)

Mitigating toxicities related to epcoritamab in follicular lymphoma: insights from EPCORE NHL-1

(1:41)

Epcoritamab + R-Mini-CHOP in previously untreated DLBCL: insights from EPCORE NHL-2

(2:24)

Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2

(1:11)

Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndrome

(1:9)

EPCORE CLL-1: An Advance in Treating Relapsed/Refractory Chronic Lymphocytic Leukemia

(10:45)

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

(5:36)

Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1

(2:6)

Genmab and AbbVie Present New Epcoritamab Data at EHA 2023

(8:)

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

(5:57)